Literature DB >> 7080130

Hyperglycemia, recognized and unrecognized, as a risk factor for stroke and transient ischemic attacks.

M C Riddle, J Hart.   

Abstract

Glycosylated hemoglobin concentration (GHb), which is considered an indication of glycemia over the preceding several months, was examined in 50 patients hospitalized for recent stroke or transient ischemic attacks (TIA), and compared to that in several reference populations. Patients with stroke or TIA had GHb (mean %A1 +/- SD, 10.2 +/- 2.3) higher than in hospital controls without cerebrovascular disease (8.3 +/- 0.9, p less than 0.005), and equivalent to values for ambulatory diabetic patients treated with diet or diet plus oral agents (9.5 +/- 2.4) or with insulin (10.7 +/- 2.9). Twenty percent (10/50) of the stroke/TIA group were previously known to have abnormal glucose tolerance or diabetes; when this subgroup was excluded, there remained 42% of the original group (21/50) with abnormal GHb (greater than 10% A1) not previously known to have hyperglycemia, and the difference between GHb values for the stroke/TIA patients not known to have glycemic abnormality and for the hospital control group remained significant (p less than 0.005). Sixty-two percent of stroke/TIA patients (31/50) were under treatment for glycemic abnormality, or had high GHb, or both. The high prevalence of elevated GHb in this population could not be attributed to a relationship to age, sex, smoking history, hypercholesterolemia, or hypertension. We conclude that hyperglycemia commonly precedes stroke and TIA, is usually unrecognized, and has been under-appreciated as a risk factor for cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7080130     DOI: 10.1161/01.str.13.3.356

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  15 in total

Review 1.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

2.  Stroke topography and outcome in relation to hyperglycaemia and diabetes.

Authors:  L Kiers; S M Davis; R Larkins; J Hopper; B Tress; S C Rossiter; J Carlin; S Ratnaike
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-04       Impact factor: 10.154

3.  Diabetes mellitus and early mortality from stroke.

Authors:  S M Oppenheimer; B I Hoffbrand; G A Oswald; J S Yudkin
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-12

4.  Diabetes mellitus and early mortality from stroke.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-09

5.  A comparison of the early development of ischemic brain damage in normoglycemic and hyperglycemic rats using magnetic resonance imaging.

Authors:  N C Huang; J Wei; M J Quast
Journal:  Exp Brain Res       Date:  1996-04       Impact factor: 1.972

Review 6.  Risk factors in stroke.

Authors:  P Mustacchi
Journal:  West J Med       Date:  1985-08

7.  The prognostic value of blood glucose and glycosylated haemoglobin estimation in patients with stroke.

Authors:  N H Cox; J W Lorains
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

8.  The contributions of individual factors to thromboembolic stroke.

Authors:  J B Henrich; R I Horwitz
Journal:  J Gen Intern Med       Date:  1989 May-Jun       Impact factor: 5.128

9.  Glycosylated hemoglobin for diagnosis of prediabetes in acute ischemic stroke patients.

Authors:  Branko N Huisa; Gulmohor Roy; Jorge Kawano; Ronald Schrader
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-07-17       Impact factor: 2.136

10.  The prevalence of diabetes mellitus and an assessment of methods of detection among a community of elderly Chinese in Hong Kong.

Authors:  J Woo; R Swaminathan; C Cockram; C P Pang; Y T Mak; S Y Au; J Vallance-Owen
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.